Heart Disease in Pregnancy Program, Saint Luke's Hospital of Kansas City, 4401 Wornall Road PEET Center, Kansas City, MO 64111, USA; University of Missouri-Kansas City School of Medicine, 4401 Wornall Road PEET Center, Kansas City, MO 64111, USA.
University of Missouri-Kansas City School of Medicine, 4401 Wornall Road PEET Center, Kansas City, MO 64111, USA; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
Cardiol Clin. 2021 Feb;39(1):33-54. doi: 10.1016/j.ccl.2020.09.011. Epub 2020 Nov 2.
Cardiovascular disease and cardiovascular disease-related disorders remain among the most common causes of maternal morbidity and mortality in the United States. Due to increased rates of obesity, delayed childbearing, and improvements in medical technology, greater numbers of women are entering pregnancy with preexisting medical comorbidities. Use of cardiovascular medications in pregnancy continues to increase, and medical management of cardiovascular conditions in pregnancy will become increasingly common. Obstetricians and cardiologists must familiarize themselves with the pharmacokinetics of the most commonly used cardiovascular medications in pregnancy and how these medications respond to the physiologic changes related to pregnancy, embryogenesis, and lactation.
心血管疾病和心血管疾病相关疾病仍然是美国产妇发病率和死亡率的最常见原因之一。由于肥胖率增加、生育年龄推迟和医疗技术的进步,越来越多的女性在怀孕前就已经患有合并症。心血管药物在怀孕期间的使用继续增加,因此,妊娠期间心血管疾病的医学管理将变得越来越常见。妇产科医生和心脏病专家必须熟悉妊娠期间最常用的心血管药物的药代动力学,以及这些药物如何应对与妊娠、胚胎发生和哺乳相关的生理变化。